Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Libin Yan

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Nucleic Acids Research|September 23, 2021
OncoSplicing: an updated database for clinically relevant alternative splicing in 33 human cancersYangjun Zhang, Xiangyang Yao, Hui Zhou, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 21, 2020
HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395Guoliang Sun, Hui Zhou, Ke Chen, et al.
Journal of Cancer|July 11, 2019
The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal TherapyHeng Li, Zhize Wang, Yucong Zhang, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 9, 2023
Retraction Note: HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395Guoliang Sun, Hui Zhou, Ke Chen, et al.
Theranostics|January 6, 2022
Erratum: Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: ErratumLibin Yan, Beichen Ding, Haoran Liu, et al.
Theranostics|January 6, 2022
Erratum: Sulforaphane elicts dual therapeutic effects on Renal Inflammatory Injury and crystal deposition in Calcium Oxalate Nephrocalcinosis: ErratumHaoran Liu, Xiaoqi Yang, Kun Tang, et al.
American Journal of Physiology. Renal Physiology|May 16, 2019
Pioglitazone decreased renal calcium oxalate crystal formation by suppressing M1 macrophage polarization via the PPAR-γ-miR-23 axisZhiqiang Chen, Peng Yuan, Xifeng Sun, et al.
Frontiers in Molecular Biosciences|June 14, 2021
Transcription Factors BARX1 and DLX4 Contribute to Progression of Clear Cell Renal Cell Carcinoma <i>via</i> Promoting Proliferation and Epithelial-Mesenchymal TransitionGuoliang Sun, Yue Ge, Yangjun Zhang, et al.
Theranostics|November 23, 2019
Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinomaLibin Yan, Beichen Ding, Haoran Liu, et al.
Frontiers in Molecular Biosciences|November 21, 2022
Corrigendum: Transcription factors BARX1 and DLX4 contribute to progression of clear cell renal cell carcinoma <i>via</i> promoting proliferation and epithelial-mesenchymal transitionGuoliang Sun, Yue Ge, Yangjun Zhang, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Nucleic Acids Research|September 23, 2021
OncoSplicing: an updated database for clinically relevant alternative splicing in 33 human cancersYangjun Zhang, Xiangyang Yao, Hui Zhou, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 21, 2020
HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395Guoliang Sun, Hui Zhou, Ke Chen, et al.
Journal of Cancer|July 11, 2019
The Immune Checkpoint Regulator PDL1 is an Independent Prognostic Biomarker for Biochemical Recurrence in Prostate Cancer Patients Following Adjuvant Hormonal TherapyHeng Li, Zhize Wang, Yucong Zhang, et al.
Journal of Experimental & Clinical Cancer Research : CR|February 9, 2023
Retraction Note: HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395Guoliang Sun, Hui Zhou, Ke Chen, et al.
Theranostics|January 6, 2022
Erratum: Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma: ErratumLibin Yan, Beichen Ding, Haoran Liu, et al.
Theranostics|January 6, 2022
Erratum: Sulforaphane elicts dual therapeutic effects on Renal Inflammatory Injury and crystal deposition in Calcium Oxalate Nephrocalcinosis: ErratumHaoran Liu, Xiaoqi Yang, Kun Tang, et al.
American Journal of Physiology. Renal Physiology|May 16, 2019
Pioglitazone decreased renal calcium oxalate crystal formation by suppressing M1 macrophage polarization via the PPAR-γ-miR-23 axisZhiqiang Chen, Peng Yuan, Xifeng Sun, et al.
Frontiers in Molecular Biosciences|June 14, 2021
Transcription Factors BARX1 and DLX4 Contribute to Progression of Clear Cell Renal Cell Carcinoma <i>via</i> Promoting Proliferation and Epithelial-Mesenchymal TransitionGuoliang Sun, Yue Ge, Yangjun Zhang, et al.
Theranostics|November 23, 2019
Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinomaLibin Yan, Beichen Ding, Haoran Liu, et al.
Frontiers in Molecular Biosciences|November 21, 2022
Corrigendum: Transcription factors BARX1 and DLX4 contribute to progression of clear cell renal cell carcinoma <i>via</i> promoting proliferation and epithelial-mesenchymal transitionGuoliang Sun, Yue Ge, Yangjun Zhang, et al.
Pageof 5